oper resili focu post altria
 ith altria announc today ceo ard illard contract take temporari leav absenc
yesterday announc shut dow sole manufactur facil virginia tw eek investor ill
increasingli focu busi resili ill includ manag bandw idth factori footprint suppli chain manag
compani altria cfo illiam gifford jr ill assum ard respons till return
evolv challeng ith know case http //w orldomet info/coronavirus/ mani
undetect altria could see new case factori reopen difficult altria test everi employe enter facil
everi day shortag test capac nation level altria detect new infect post plant reopen might
need shut dow manufactur plant challeng appli everi busi today
may seem bleak life hk china return rel normal better day ahead us view
back busi analysi
japan tobacco face similar issu hen post fukushima disast suppli chain impact jt lost lot market
share time hich never fulli recov believ compani plan proactiv could emerg side
disrupt rel unscath
one key ay plan ill build inventori ill absorb ork capit ever cost ork capit risk-
free rate minim compar cost lose market share manufactur oper ere disloc tobacco
gross margin busi compani store lot leaf locat year lot empti space factori
volum declin year altria ere increas inventori month month ould absorb
 ork capit per back-of-the-envelop calcul alw ay revers hen situat normalis
tobacco leaf clove account pmi cost good sold
 think tobacco compani need assum ill relat disrupt next month assum that
long take scientist find vaccin inde consum current build inventori anticip prolong
disrupt think retail holesal manufactur ill/ne also build inventori increas resili ould
increas counter-parti credit risk manufactur hich ould need close monitor
implic compani
altria shutdow virginia manufactur eek impli launch like delay ell might thought good
new sw edish match sw edish match manufactur zyn one facil kentucki capacity-constrain hat prevent
impact employe facil current case kentucki vs virginia
bat factori pmi global make resili issu one facil ever think
similar logic appli may ell also need build month inventori
altria suspend oper richmond manufactur facil tw eek identifi second employe ho
test posit coronaviru altria believ tw month inventori cigarett three month inventori cigar
across ow manufactur retail holesal note altria one manufactur facil us virginia hile bat
tw us suppli chain integr like emerg key point focu across compani
bat oper netw ork manufactur factori spread around orld europ cigarett manufactur facil
 believ bat lot flexibl sustain suppli chain disrupt due
bat-own tobacco facil bat factori footprint global like manag
philip morri ow pt oper ow ned total manufactur facil dec across globe among
factori produc heat tobacco unit largest manufactur facil term volum locat indonesia turkey
philippin russia poland lithuania itali
scandinavia tobacco group cover withdraw guidanc
stg note author across orld implement measur contain fight spread coronaviru
see restrict consum movement hich affect normal purchas consumpt pattern lead
situat significantli less transpar consum behaviour consumpt retail custom chang
behaviour tri respond constantli chang environ situat develop day day countri
around orld current unabl accur assess short-term impact develop busi henc
 suspend financi guidanc pend clarif gener situat market develop
impact busi expect consum behaviour normal follow ing pandem situat consid effect
extel vote begun
vote begun extel survey extrem import us key metric judg
appreci research pleas vote ith link take minut time make huge differ
us ould grate support follow ing
beverag laurenc hyatt ew mitchel
link previou research
pmi detail fx sensit
us tobacco ill opec benefit repeat
altria/bat bloomberg exit take polit tail risk tabl
altria/bat feb cig volum shipment vs nielsen
inc pmi grow ep post feb
imperi brand plc orsen ngp loss lead groundhog day feb
altria/bat jan cig volum shipment vs nielsen feb
inc last ep cut juul ritedow feb
british american tobacco plc rai us volum declin jan
altria/bat dec cig volum shipment vs nielsen jan
global consum stapl jan
global tobacco fda e-cig ban advantag bat juul flavor cigar ban jan
sw edish match address bearish pushback dec
japan tobacco japan close cigarillo tax gap dec
altria/bat report us cig volum bat e-cig begin grow rapidli dec
european consum stapl trump back aw ay ban e-cig flavor focu turn congress
altria/bat fda drop us cig nicotin reduct return menthol ban flavor cigar rulemak also get delay
altria/bat report us cig volum e-cig stall
imperi brand plc new chairperson dividend stabil still grow ing ep support stock
british american tobacco plc meet ith cfo
inc long journey rebuild trust
global tobacco juul uk europ financi oct
sw edish match zyn off-set flavor cigar oe pt sek oct
european consum stapl vape epidem fallaci e-cig flavour ban oct
european consum stapl pm-mo chang exchang ratio aug
inc iqo back track upgrad ow juli
european consum stapl smoke signal second deriv us volum turn posit atermelon blueberri
mentholet analys possibl implic menthol ban dec
smoke signal kick tyre ith juul sep
smoke signal juul disrupt come tobacco juli
imperi brand initi heat burn dow may
gaurav jain herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill directli
indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
research report prepar hole part equiti research analyst base outsid us ho
registered/qualifi research analyst ith finra
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
research analyst employ outsid us affili barclay capit inc registered/qualifi research analyst
 ith finra non-u research analyst may associ person barclay capit inc hich finra member
therefor may subject finra rule restrict commun ith subject compani public appear
trade secur held research analyst account
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target altria base price-to-earnings valuat last tw decad altria trade
averag fw multipl higher cigarett volum declin regulatori uncertainti manag attempt sell us
busi p/core tobacco ep pressur multipl near term valu altria price-to-earnings add addit
valu per share juul crono get price target usd
risk may imped achiev barclay research valuat price target fda regul drastic
rate price target histori
prior intra-day chang may publish rate price target secur ere
histor stock price price target may adjust stock split dividend
valuat methodolog consid british american tobacco valuat use p/e-bas approach deriv
target multipl ith refer bat tobacco peer group make adjust busi mix leverag grow th
prospect appli multipl ep result round price target
risk may imped achiev barclay research valuat price target regulatori agenda
fda ill domin headlin everi month like creat period heighten volatil altria aggress ith
iqo could lead signific up-front invest disrupt market share equilibrium damag market profit
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
